Johnson & Johnson gains on another beat and raise quarter
) beat on the top and bottom line in the third quarter and raised its guidance for the full year on both as well. Shares gained 1.5% immediately following the strong results.rose 6.8% to $21.4 billion, topping the consensus of $21.04 billion. Adjusted EPS rose 19.3% to $2.66, topping the consensus of $2.51.
"Johnson & Johnson delivered strong results and significant pipeline advances in the third quarter, providing a solid foundation for future sustained growth," CEO Joaquin Duato said."With a sharpened focus on Innovative Medicine and MedTech solutions, Johnson & Johnson is innovating across the spectrum of healthcare and is poised to deliver the medical breakthroughs of tomorrow.
Looking to the full year, the company now sees Adjusted Operational Sales up 7.2%-7.7%, versus its prior guidance of 6.2%-7.2%. Adjusted EPS is seen at $10.07-$10.13, up from $10-$10.10 and above the consensus of $10.03.We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other.
{username} Just Now Share Follow this postUnfollow this post Save Saved. See Saved Items . This comment has already been saved in your Saved Items Author's response{commentContent} Reply 00 Report {username} Just NowAuthor's response Share Follow this postUnfollow this post Save Saved. See Saved Items .
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bank of America reports, Johnson & Johnson, retail sales: 3 things to watchBank of America reports, Johnson & Johnson, retail sales: 3 things to watch
Read more »
Johnson & Johnson Reports Earnings Tuesday. What to ExpectAn update in August after the split leaves investors with fewer questions for Tuesday's results.
Read more »
Johnson & Johnson earnings: What to expectJohnson & Johnson is not expected to produce big surprises in its earnings release due Tuesday
Read more »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Read more »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Read more »
Johnson & Johnson's stock climbs after company beats earnings estimates and raises profit guidanceJohnson & Johnson raised its full year EPS guidance and lifted the midpoint of its sales range
Read more »